

AMENDMENTS TO THE CLAIMS:

The following listing of claims will replace all prior versions, and listings, of claims in the Application:

Listing of Claims:

56-104. (Canceled)

105. (Currently Amended) A method of determining whether an analyte polynucleotide is present in a test sample in an amount greater or less than a pre-determined value, comprising the steps of:

obtaining a test sample to be analyzed for the presence of said analyte polynucleotide, said analyte polynucleotide being selected from the group consisting of a viral polynucleotide, a bacterial polynucleotide, a fungal polynucleotide, a protozoan polynucleotide, and a human polynucleotide;

combining said test sample with an amount of a pseudo target;

co-amplifying in a polynucleotide amplification reaction the pseudo target and any analyte polynucleotide contained in said test sample to produce amplification products that include a pseudo target amplicon and an analyte amplicon, wherein said analyte amplicon is [[present]] produced in an amount that is dose-dependent on the amount of said analyte polynucleotide present in said test sample; and

quantitatively detecting said analyte amplicon using a detection system calibrated to indicate a positive result upon detecting an amount of analyte amplicon arising from co-amplification of said amount of said pseudo target and an amount of analyte polynucleotide equal to or greater than said pre-determined value, wherein [[a]] said positive result indicates that said analyte polynucleotide is present in said test sample in an amount equal to or greater than said pre-determined value, [[and]] wherein a negative result indicates that said analyte polynucleotide is present in said test sample in an amount less than said pre-determined value, and wherein said positive result and said

negative result are determined without reference to the amount of pseudo target amplicon synthesized in the co-amplifying step.

106. **(Previously Presented)** The method of Claim 105, further comprising a step for detecting the pseudo target amplicon produced in the co-amplifying step.

107. **(Canceled)**

108. **(Previously Presented)** The method of Claim 105, wherein said detection system comprises luminometry.

109. **(Previously Presented)** The method of Claim 105, wherein said analyte polynucleotide is a viral polynucleotide.

110. **(Previously Presented)** The method of Claim 109, wherein said viral polynucleotide is selected from the group consisting of an HIV-1 polynucleotide, an HIV-2 polynucleotide, an HBV polynucleotide, and an HCV polynucleotide.

111-115. **(Canceled)**

116. **(Previously Presented)** The method of Claim 105, wherein said detection system is selected from the group consisting of a chemiluminescent detection system, a fluorescent detection system, an optical detection system, and an electro-chemical detection system.